Neurogeneticists focus on the genetic underpinnings of neurological diseases, working to uncover how genetic mutations influence the structure and function of the nervous system. Their research spans a variety of conditions, from rare hereditary disorders to more common diseases like Alzheimer's, Parkinson's, and epilepsy. By identifying gene mutations and understanding their impacts on neuronal development, neurogeneticists help explain the pathophysiology of these conditions. They utilize cutting-edge technologies such as whole-genome sequencing, CRISPR gene editing, and transcriptomics to unravel complex genetic interactions. In doing so, they uncover biomarkers that improve diagnostic accuracy and allow for personalized treatment strategies. Neurogeneticists also examine how environmental factors interact with genetic predispositions to influence disease onset and progression. Their work not only aids in the development of gene therapies but also offers critical insights into the mechanisms of neuroplasticity and aging. Through their contributions, neurogeneticists are advancing precision medicine, ultimately improving outcomes for patients with genetic neurological disorders. Furthermore, their research on neurogenetics contributes to the ongoing exploration of rare diseases and provides valuable resources for genetic counseling and clinical decision-making. This multidisciplinary approach ensures a comprehensive understanding of both inherited and acquired neurological conditions, enhancing therapeutic prospects.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States